Use of the peptide bioregulator Liberol to restore human functional reserves under extreme exposures
S. V. Padalko · 2003 · Primary source linked above
What does this source report?
Padalko identifies Liberol as thyroliberin/TRH (pyroglutamyl-His-Pro-amide) and reports human hypoxia, motion-stress and performance experiments. Cohort structure and numerical results require the original scan.
- Population and setting
- Human occupational experiments; dissertation transcription
- Evidence type
- Not classified
- Preparation
- See the original report; formulation details require verification.
- Source language
- See source; English abstract or translated patent text where available
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Original scan, formulation and allocation require verification.
- Not a modern controlled trial or evidence supporting unsupervised altitude use.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected original-source text checked; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: S. V. Padalko. Use of the peptide bioregulator Liberol to restore human functional reserves under extreme exposures Primary source linked above 2003.
Molekul research summary: https://molekul.io/research/rp-liberol-padalko-2003. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry